SPH5030 not checked

Shanghai Pharmaceuticals Holding Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Main trialPhase 2
“To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.”In the company’s words, NCT06434597 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Dec 2026 A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
Phase 1Completed 25 Mar 2024 A Food Effect Study of SPH5030 Tablets.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SPH5030

Following is part of Solo: you see every change to SPH5030 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in